Presented at the 5th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit:
www.global-engage.com
With the recent gift of $100 million, the Duchossois Family Institute was established, providing UChicago with the resources to develop models for translating microbiome research. Matt Martin discusses their plans for expanding the support provided to faculty and the mechanisms for launching their startups and technologies.
6. Combined Innovation Resources
6
– Chicago City Healthtech Incubator
▪ Private Equity Conference
– Exchange with Investors
▪ NSF I-Corps Site ▪ Chicago Microbiome Conference
– Entrepreneurship Education – Exchange with Industry Partners
▪ Tech Commercialization ▪ Tech Venture Fellows
– Tech Transfer – Entrepreneurs-in-Training
▪ Innovation Fund ▪ Fabrication Lab
– Gap Funding – Rapid proto-typing
▪ Chicago Innovation Mentors ▪ Polsky Exchange
– Team Based Mentoring – Co-working space with programming
▪ MATTER membership ▪ New Venture Challenge
– Business plan competition and accelerator
7. ▪ Data sciences, Wet Labs, Start-ups, Corporate Labs, & Research Partners
– Army Research Laboratory
– University of Wisconsin
– UIUC Engineering
– Northwestern University
– Argonne National Laboratory
7
9. Duchossois Family Institute
$100M gift to create a new science of wellness using
genetics, immunology, microbiome, and bioinformatics
Driving Impact
9
10. Chicago Microbiome Conference
Exchange with Industry Partners
Tech Venture Fellows
Entrepreneurs-in-Training
Fabrication Lab
Rapid proto-typing
Polsky Exchange
Co-working space with programming
New Venture Challenge
Business plan competition and accelerator
Launchpad
NSF I-Corps Site
Entrepreneurship Education
Tech Commercialization
Tech Transfer
Innovation Fund
Gap Funding
Chicago Innovation Mentors
Team Based Mentoring
MATTER membership
Chicago City Healthtech Incubator
10
12. Life Changing: Monoclonal Microbials
Founded by Flagship
A platform integrating expertise in
microbiology, immunology, pharmacology
and computational biology
Licensed microbiome technology from lab
of Tom Gajewski at The University of
Chicago amongst other IP
12
13. Technology: Novel, synthetic pharmaceuticals have been identified to
prevent and treat life-threatening food allergies. The drug candidates are
being screened in a humanized mouse developed specifically to identify
therapeutics for food allergy and elucidating the mechanism of action. The
model gives greater insight into allergic sensitivity, leading to better
treatments.
Markets/Business Model: We are a
research intensive pharmaceutical company
actively seeking partners for clinical
development. Initial target indications are peanut
and cow’s milk allergy, the two most prevalent
food allergies. We aim to expand to treat all of the
roughly 15 million Americans with food allergies.
Stage: Preclinical discovery and optimization.
Lead drug candidate is being tested for efficacy
and dose optimization in peanut allergy murine
model. Cow’s milk allergy will follow in 2-3
months. Have completed seed round of funding
for these studies.
IP: Provisional application has been prepared
and ready to file. IP is owned by University of
Chicago. ClostraBio has option to license.
Next Steps: Complete financing of $3-5M for
preclinical safety studies for Phase 1 clinical
trials, complete the executive team, and identify /
secure development partner. A subsequent
financing of $15-20M is expected to launch
Phase 1 trials and expand the pipeline
More Information:
For more information or any inquiries,
contact: john.w.colson@clostrabio.com
www.clostrabio.com
Non-Confidential Deck
One-page Summary
Developing therapeutics for life-threatening food allergies
CATHRYN NAGLER, PhD, President and Co-founder
JEFFREY HUBBELL, PhD, Co-founder
BRUCE HAMAKER, PhD, Co-founder
JOHN COLSON, PhD, Project Manager
13
14. Technology: Novel, highly specific peptides have been developed to target
virulent forms of fungi. These modified peptides are based on a naturally
occurring peptide which has been shown to maintain fungal
commensalism by deterring virulence. Unlike other anti-fungal and anti-
biotic agents, these peptides can be used prophylactically to prevent
fungal disease in high-risk patients, without ablating healthy microbes,
and have the potential to be safer than the current standard ofcare.
Business Opportunity: The immediate
addressable market for oncology patients is
$1.2B per year. More broadly, fungal infection
and microbial dysbiosis especially affects
patients who are immunocompromised (5M)
or diabetic (30M).
Stage: Preclinical. The naturally occurring
peptide has been shown to inhibit C. Albicans
infection in colonized mouse models (in vivo)
and to prevent expression of virulence factors
in vitro. Modified versions of the naturally
occurring peptide have also demonstrated
initial efficacy in vitro.
Next Steps: High throughput screen of
additional compounds and selection of leads
for in vivo validation. Discussions with future
investors and development partners have been
initiated.
IP: A provisional patent application hasbeen
filed that covers composition of matter and
prophylactic/intervention usage indications.
For More Information Contact:
mminter@uchicago.edu
mvajani@chicagobooth.edu
Preventing Fungal Disease
Gene Chang
Chief Medical
Officer
Joe Pierre
Chief Scientific
Officer
Katie Harris
Lead Scientist
Myles Minter
BusinessLead
MonicaVajani
Business Lead
14
15. composition detection, capable of identifying and quantifying gram positive and
negative bacteria, viruses, fungi, and more in 20 minutes while using little
energy. This is achieved by combining multiple novel, patented technologies
onto a single unified platform – advanced intake and microfluidic handling,
unique cell rupture and DNA recovery technology to maximize identifiable
pathogens, and gold-nanoparticle ultraPCR allowing for rapid, low-energy
quantification.
Markets/Business Model: We are
evaluating multiple potential markets, including air
and water quality monitoring, clinical trial support,
food safety, pharmaceutical development, home
use, and more.
Stage: Seed stage, pre-company formation.
Current activities are finalizing proof of concept,
evaluating partnership opportunities, and market
research. Conversations with potential partners in
multiple different markets ongoing.
Next Steps: Raise $50 - $100K of seed money
to finish alpha prototype and complete proof of
principle studies. Once complete, additional
fundraising will support beta proto-type for specific
markets and build out leadership team.
IP: Patents and patent applications on individual
component technologies. Owned by the University of
Chicago and Argonne National Laboratory.
Developing an automated sensor for microbial composition detection
Technology: A low-cost automated sensor for environmentalmicrobial
JACK GILBERT, PhD – Lead Investigator
PHIL LAIBLE, PhD – Co-investigator
SAVAS TAY, PhD – Co-investigator
YOSSI WEIZMANN, PhD – Co-investigator
More Information:
For more information or inquiries, contact:
gilbertjack@uchicago.edu
15
16. Presented at the 5th Microbiome R&D and
Business Collaboration Forum: USA
To find out more, visit:
www.global-engage.com
16
